医药行业分析
- (2021-12-23)
欧盟扩大了gülid Veklury(Remdesivir)的适应症:治疗不需要补充氧气 发展为严重COVID的风险很高
(2021-12-23)- (2021-12-23)
- (2021-12-23)
- (2021-12-22)
- (2021-12-22)
- (2021-12-22)
- (2021-12-22)
- (2021-12-22)
- (2021-12-22)
- (2021-12-21)
- (2021-12-21)
- (2021-12-21)
- (2021-12-21)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-20)
- (2021-12-17)
- (2021-12-17)
- (2021-12-17)
- (2021-12-17)
- (2021-12-17)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
淋巴瘤(NHL)新药!信达生物/Incyte口服PI3Kδ抑制剂parsaclisib:中国II期研究总缓解率为91.7%!
(2021-12-16)近20年淋巴瘤(DLBCL)一线治疗取得重大进展!罗氏CD79b靶向抗体结合药物Polivy:将疾病恶化/死亡风险降低27%!
(2021-12-16)- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-16)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-14)
- (2021-12-13)
- (2021-12-13)
- (2021-12-13)
- (2021-12-13)